Correction: Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer



Summary

A multicenter phase Ib/II clinical trial investigated the efficacy and safety of combining durvalumab and tremelimumab with paclitaxel as a second-line treatment for metastatic gastric cancer. The study focused on patients selected based on specific biomarkers. This combination therapy aims to enhance the immune system’s response to the cancer. The trial is designed to assess the optimal dosage in Phase Ib and evaluate the treatment’s effectiveness in Phase II among biomarker-positive patients. The results from this study could potentially offer a new treatment option for this patient population with limited alternatives.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!